قالب وردپرس درنا توس
Home / Business / Biogen's results leave the Alzheimer's puzzle unresolved

Biogen's results leave the Alzheimer's puzzle unresolved



It's hard not to rejoice when it's shown that a drug has a very real potential to help people with Alzheimer's ̵

1; a common, devastating, and currently incurable disease. However, some reluctance is required to respond to the results published late Wednesday for the treatment developed by Biogen Inc. and Eisai Co.

. The drug, BAN2401, significantly slowed cognitive decline after 18 months of high-dose treatment, depending on how you measure it. Regardless of the qualification, this is an absolutely promising result and the data are better than I, a skeptic to Alzheimer's studies, in some ways expected. But there are many more tests before anyone can be sure of this result, and it will take a long time.

Taken together, this is not the home run that some investors have been looking for, and they have already begun adapting to this reality. After Biogen's shares were pushed to a three-year high ahead of the release of the results, Wednesday's shares fell by more than 10 percent after-hours.

Early verdict

Biogen shares rose in anticipation of Alzheimer's data Wednesday, but the early reaction in trading outside the hours is quite negative

Source: Bloomberg


There are big differences in the way how Alzheimer's affects people and how they progress, which is a reason for all previous efforts to treat them has failed spectacularly. Many disappointments in the past were based on the same theory of treatment of the disease, the BAN2401, known as the amyloid hypothesis.


Source link